GLP-1 drugs in haematology: beyond weight loss The Lancet Haematology ++... ++

GLP-1 drugs in haematology: beyond weight loss The Lancet Haematology https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00002-5/fulltext?dgcid=raven_jbs_etoc_email Feb 2026 Volume 13Number 2e55-e118 https://www.thelancet.com/journals/lanhae/issue/vol13no2/PIIS2352-3026(26)X2001-4 Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study Jonas S Heitmann, MDa,b,c,† ∙ Yacine Maringer, PhDb,c,† ∙ Susanne Jung, MDa,b,c,† ∙ Marcel Wacker, MScb,c ∙ Christopher Hackenbruch, MDa,b ∙ Mark Polster, MScb,k,n ∙ et al https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00323-0/fulltext?dgcid=raven_jbs_etoc_feature_lanhae Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England Stephen Kaptoge, PhDa,b,c,* ∙ Amy McMahon, PhDa,b,c,* ∙ Yaning Wu, MSca,b,c ∙ Philippe T Gilchrist, PhDa,f,g ∙ Matthew Walker, PhDa,b,c ∙ Susan Mehenny, RGNh ∙ et al https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00319-9/fulltext?dgcid=raven_jbs_etoc_feature_lanhae